Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2010-05-06
2011-10-04
Minnifield, Nita M (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Reexamination Certificate
active
08029982
ABSTRACT:
Biomarkers for sepsis and resulting mortality can be detected by assaying blood samples. Changes in the concentration of the biomarkers can be used to indicate sepsis, risk of sepsis, progression of sepsis, remission from sepsis, and risk of mortality. Changes can be evaluated relative to data sets, natural or synthetic or semisynthetic control samples, or patient samples collected at different time points. Some biomarkers' concentrations are elevated during disease and some are depressed. These are termed informative biomarkers. Some biomarkers are diagnostic in combination with others. Individual biomarkers may be weighted when used in combinations. Biomarkers can be assessed in individual, isolated or assays, in parallel assays, or in single-pot assays.
REFERENCES:
patent: 4531936 (1985-07-01), Gordon
patent: 5639617 (1997-06-01), Bohuon
patent: 5710008 (1998-01-01), Jackowski
patent: 5965375 (1999-10-01), Valkirs
patent: 6190872 (2001-02-01), Slotman
patent: 6207395 (2001-03-01), Valkirs et al.
patent: 6303321 (2001-10-01), Tracey et al.
patent: 6503722 (2003-01-01), Valkirs
patent: 6673562 (2004-01-01), Shi
patent: 6743595 (2004-06-01), Gosselin et al.
patent: 6828110 (2004-12-01), Lee et al.
patent: 6908739 (2005-06-01), Buechler et al.
patent: 7052858 (2006-05-01), Gray et al.
patent: 7235368 (2007-06-01), Bergmann et al.
patent: 7329738 (2008-02-01), Lee et al.
patent: 7374888 (2008-05-01), Valkirs et al.
patent: 7393647 (2008-07-01), Valkirs et al.
patent: 2001/0021511 (2001-09-01), Valkirs et al.
patent: 2002/0127618 (2002-09-01), Gray et al.
patent: 2003/0109420 (2003-06-01), Valkirs et al.
patent: 2004/0097460 (2004-05-01), Ivey et al.
patent: 2004/0121343 (2004-06-01), Buechler et al.
patent: 2004/0203083 (2004-10-01), Buechler et al.
patent: 2004/0253637 (2004-12-01), Buechler et al.
patent: 2005/0148029 (2005-07-01), Buechler et al.
patent: 2005/0164238 (2005-07-01), Valkirs et al.
patent: 2005/0196817 (2005-09-01), Kingsmore et al.
patent: 2007/0092911 (2007-04-01), Buechler et al.
patent: 2007/0172906 (2007-07-01), Valkirs et al.
patent: 2008/0050832 (2008-02-01), Buechler et al.
patent: 2009/0004755 (2009-01-01), Lee et al.
patent: 2010/0240078 (2010-09-01), Lee et al.
patent: WO 98/14582 (1998-04-01), None
patent: WO 03/073099 (2003-09-01), None
patent: WO 2004/043236 (2004-05-01), None
patent: WO 2004/044555 (2004-05-01), None
patent: WO 2004/059293 (2004-07-01), None
patent: WO 2004/044555 (2004-09-01), None
patent: WO 2004/087949 (2004-10-01), None
patent: WO 2004/059293 (2005-03-01), None
patent: WO 2005/033327 (2005-04-01), None
patent: WO 2005/048823 (2005-06-01), None
patent: WO 2004/043236 (2005-07-01), None
patent: WO 2004/087949 (2005-10-01), None
patent: WO 2005/048823 (2005-11-01), None
patent: WO 2005/033327 (2006-08-01), None
Becker et al. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: A journey from calcitonin back to its precursors. J. clin. endocrinol. Metab. 2004;89(4): 1512-1525.
Bernard, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. Mar. 8, 2001;344(10):699-709.
Biasucci, L.M. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease.Circulation. 2004;110:e560-e567.
Bone, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-53.
Bossink, et al. Plasma Levels of the Chemokines Monocyte Chemotactic Proteins-1 and -2 Are Elevated in Human Sepsis. Blood 1995;86:3841-3847.
Charpentier, et al. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med. Mar. 2004;32(3):660-5.
Chinnaiyan, et al. Short Communication Molecular signatures of sepsis: Multiorgan gene expression profiles of systemic inflammation. Am J Pathol. Oct. 2001;159(4):1199-1209.
C-reactive protein. Medline Plus. http:www.nlm.nih.gov/medlineplus/ency/article/003356.htm.
Cruse, et al. Illustrated Dictionary of Immunology, 2nd edition. CRC Press. 2003; 539.
Delogu, et al. Serum neopterin and soluble interleukin-2 receptor for prediction of a shock state in gram-negative sepsis. J Crit Care. Jun. 1995;10(2):64-71.
Doellner, et al. Increased serum concentrations of soluble tumor necrosis factor receptors p55 and p75 in early onset neonatal sepsis. Early Human Development. Oct. 1, 1998;52(3)251-261.
Dollner, et al. Inflammatory mediators in umbilical plasma from neonates who develop early-onset sepsis. Biol Neonate. Jul. 2001;80:41-7-2404 PCT/US2004031769.
Dorland's Medical Dictionary. http://www.mercksource.com/pp/us/cns/cns—hl—dorlands—split.jsp?pg=/ppdocs/us/common/dorlands/dorland/seven/000095957.htm. Accessed on Oct. 6, 2008).
Fassbender, et al. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. Stroke. Oct. 1999;30(10):2101-4.
FDA 510-k summary K040887. B•R•A•H•M•S Diagnostica. Prepared on Dec. 22, 2004.
Freitag, et al. Plasma Brain Natriuretic Peptide Levels and Blood Pressure Tracking in the Framingham Heart Study. Hypertension. 2003;41:978-983.
Gabay, et al. Interleukin 1 Receptor Antagonist (IL-1Ra) Is an Acute-Phase Protein J. Clin. Invest. 1997; 99(12):2930-2940.
Hausfater, et al. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin Infect Dis. Apr. 1, 2002;34(7):895-901.
Hotchkiss, et al. The pathophysiology and treatment of sepsis. N Engl J Med. Jan. 9, 2003;348(2):138-50.
Hurst, et al. Use of Plasma Biomarkers at Exacerbation of Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2006;174:867-874.
iHOP (Information Hyperlinked Over Proteins), entry for CRP, downloaded from http://www.ihop-net.org/UniPub/iHOP/gs/92774.html on Jan. 16, 2007.
iHOP (Information Hyperlinked Over Proteins), entry for TNFRSF1A, p. 1, downloaded from http://www.ihop-net.org/UniPub/iHOP/gs/92774.html on Jan. 17, 2007.
Indik, et al. Detection of pulmonary embolism by D-dimer assay, spiral computed tomography, and magnetic resonance imaging. Prog. Cardiovasc. Dis. 2000; 42: 261-272.
Kimura, et al. Plasma concentration of cytokine antagonists in patients with infection following liver resection. British Journal of Surgery. Dec. 1998; 85:1631-1635.
Kinasewitz, et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism. Crit Care. 2004; 8(2): R82-R90.
Lein, et al. Metalloproteinases (MMP-1, MMP-3) and their inhibitors (TIMP) in blood plasma of patients with prostate carcinoma. Urologe A. 1998;37(4): 377-381 (English abstract only).
Liras, et al. Clinical value of an automated granulocyte elastase assay in predicting severity of acute pancreatitis. Rev Esp Enferm Dig. Sep. 1995;87(9):641-52. (In Spanish with English abstract).
Lukacs, et al. Characterization of Chemokine Function in Animal Models of Diseases. Methods. Aug. 1996;10(1):158-65.
Lundblad, et al. Endothelin concentrations in experimental sepsis: profiles of big endothelin and endothelin 1-21 in lethal peritonitis in rats. Eur J Surg. Jan. 1995;161(1):9-16.
Macias, et al. Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med. May 2004;32(5 Suppl):S223-8.
Matsumori, et al. Plasma Levels of the Monocyte Chemotactic and Activating Factor/ Monocyte Chemoattractant Protein-1 are Elevated in Patients with Acute Myocardial Infarction. J. Mol. Cell. Cardiol. 1997;29:419-423.
Mitaka, et al. Endothelin-1 and atrial natriuretic peptide in septic shock. Am Heart J. Aug. 1993;126(2):466-8.
Murdoch, et al. The role of chemokines in sepsis and septic shock. Contrib Microbiol. 2003;10:38-57.
National Institute of Health. Medical Encyclopedia. Http://www.nlm.nih.gov/medlineplus/ency/article/000666.htm.Accessed on Oct. 6, 2008.
Office action issued Mar. 4, 2009 for U.S. Appl. No. 11/690,767.
Office action issued May 29, 2009 for U.S. Appl. No. 11/543,312.
Poeze, et al. An internationa
Driscoll Mark
Kingsmore Stephen F.
Lejnine Serguei J.
Tchernev Velizar T.
Alere San Diego, Inc.
Gangle Brian J
Minnifield Nita M
Wilson Sonsini Goodrich & Rosati
LandOfFree
Biomarkers for sepsis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biomarkers for sepsis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biomarkers for sepsis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4281090